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It has recently been demonstrated that half-
lives ofxenobiotics estimated in rats can be
used to predict their half-lives in humans
using a linear model that is logarithmic in
both variables as follows:
log(t1/2h) = a + [blog(tll2r)] + e (1)
where tl/2h and tl/2r represent xenobiotic
half-lives for humans and rats, respectively,
for an array ofdifferent xenobiotics, and eis
an error term assumed to be normally dis-
tributed with a constant standard deviation,
a (1). This model was derived from a
regression analysis of over 100 xenobiotics
for which both rat and human half-life val-
ues had been reported, and could be simpli-
fied to an allometric expression:
tiI2h = a(tl/2r)b (2)
where adepends on both a and e.
The values for rat half-life used in the
former analysis ranged from about 0.02 hr to
1,776 hr. It was additionally reported that
the 80% confidence intervals for the predict-
ed human half-lives generally embraced
about a 10-fold range of predicted half-life
values and that the model accounted for
75% of the variance in the relationship
between tl/2h and tl/2r (1).
In this study, we explored the possibility
that accounting for the role ofxenobiotic lipid
solubility might provide an improvement in
the prediction ofhuman half-life values esti-
mated directly from rat half-life data. The
lipid solubility of xenobiotics would be
expected to be an important parameter in
determining the half-life relationship
between rats and humans because the adi-
pose content of humans as a percentage of
totalbodyweight is 3-4 times larger than for
rats (23% vs. 7%, respectively) (2). To
explore the effect of lipid solubility, we
examined the ability ofthe octanol:water
partition coefficient, expressed as log P, to
account for some ofthevariability remaining
in the data after use of the simple linear
expression in Equation 1. We also expanded
the number of substances with high log P
values (>6.5) to better evaluate howwell this
model and others accommodate xenobiotics
with such high log P values and hence
exremely longhalf-lives.
Methods
Average half-life values in rats and humans
for 127 xenobiotics were obtained from
the literature. The references for 103 of
those variates have been published [see
Bachmann et al. (1)]. Log P values for 102
of these xenobiotics were ascertained from
one of four resources (3-6) and represent-
ed a mix of experimentally determined or
calculated values. The influence ofthe log
P of a xenobiotic on the accuracy of its
predicted human half-life from rat half-life
data was investigated as follows.
We successively explored six different
models, ranging from the simple to the com-
plex. The models are listed in Table 1. Model
1 can be recognized as a first order Taylor
series in one variable, log t1/2r. Model 2 is a
second order Taylor series in log t1/2r. Model
3 is a first orderTaylor series in two variables,
log tl/2r and log P. Models 4-6 are second
order Taylor series' in two variables, log tl/2r
andlog P.
Two ofthe models (Models 1 and 2) were
evaluated using both the full data set (n =
127) and the more limited data set (n = 102),
which included only those substances for
which log Pvalues were available.
Models were evaluated using simple
regression analysis. The statistical parameters
of interest were the root mean square error
(RMSE) of the observed versus predicted
values; the adjusted R2 value, which is a
measure of the total variance explained by
the model; the estimate of each coefficient;
and the results of a two-tailed t-test ascer-
taining whether the coefficient value is sig-
nificantly different from zero. Differences
were considered significant at p-values
<0.05. Computations, including regression
analyses, were performed using SAS statisti-
cal software (SAS Institute, Cary, NC) run-
ning on an IBM 9672 mainframe computer
(IBM, Somers, NY).
Results
Results of the regression analyses and t-test
are given in Table 1. For the models that do
not take specific account oflog P (Models 1
and 2), it should be noted that the quadratic
model is preferred (Model 2). This becomes
apparent when comparing the graphs of
Models 1 and 2 for the full data set (Fig. 1),
where it can be seen that Model 2 better
accomodates xenobiotics with extremely
high values of t1/2r1 which also tend to be
xenobiotics with extremely large (.6.5) val-
ues for log P. Model 3 is afirst-order Taylor
series in both log tl/2r and log P, and it
yields less satisfactory results than Model 2
when applied to the same data set (i.e., the
102 xenobiotics for which log P values were
available). For comparative purposes, Model
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Table 1. Statistical results ofsixmodels usedto predicthuman half-lifefrom rathalf-life data
Coefficientestimate
Model Equation Number RMSE IF(adjusted) Coefficient and(SE) p-Value
1 logt/nh= a+ b(logt1/r) 127 0.4276 0.8312 a 0.7174(0.0390) 0.0001
b 1.0718(0.04301 0.0001
a
b
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"Thep-valueforthesetwo coefficientstogether(i.e.,collectively) is0.1128.
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2 is graphed in juxtaposition to Model 1 in
Figure 1. Model 2 is graphed with predic-
tion intervals in Figure 2; in this figure the
full data set was used.
Models 4, 5 and 6 use t12rand log P in
various second order Taylor series models
to predict human half-life. These three
models are virtually equivalent in terms of
RMSE and adjusted R2, differing by little
more than 1% from one another in RMSE
and less for R2. This fact alone leads us to
select the least complex model among
these, Model 4. In addition, we note in
Model 6 (the full quadratic model) that the
interaction term is not statistically signifi-
cant, and when that term is dropped
(resulting in Model 5), the (log p)2 term
becomes nonsignificant as well. Finally,
when the statistical significance of these
two terms is jointly tested in Model 6, the
p-value for the F-test is found to be 0.113,
as noted in Table 1. Each ofthese observa-
tions lead us to prefer Model 4 out of all
models incorporating log P. In Figure 3 the
predicted human half-lives are plotted
against actual human half-lives. Predictions
are based on Models 1-4, and the juxtapo-
sitioning ofthe regression and identitylines
is shown. On the basis ofthe values ofthe
coefficients and exponents for the regres-
sion equations, the regression lines for
Models 2 and 4 more closely approximate
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Figure 1. Comparison ofthe measured human half-lives to human half-lives predicted from rat half-lives by
Model 1 and Model 2 forthe full data set (n = 127). See Table 1 for model equations and model parameter
values. The identity and log P value are indicated for the nine compounds with the highest log P values
and/or longest half-lives. Abbreviations: MeHg, methylmercury; PnCB, 2,2',4,5,5'-pentachlorobiphenyl;
TBDD, 2,3,7,8-tetrabromodibenzo-p-dioxin; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; PnCDF, 2,3,4,7,8-
pentachlorodibenzo-p-dioxin; HxCB, 2,2',4,4',5,5'-hexachlorobiphenyl.
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the identity lines. Similar plots for Models
5 and 6 appear virtually identical to that of
Model 4 (not shown).
We also observe that the RMSE and R?
values for Model 4 appear close to those
found for Model 2. This indicates that
valid predictions can be obtained even if
log P is not available and the prediction is
based entirely on tl/2r. On the other hand,
when only the limited data set (ofxenobi-
otics with log P values available) is used, we
find that as log P is considered, RMSE is
lower, X2 is higher, and log P is statistically
significant (p = 0.020). Thus when log P is
available, these results indicate that it is
sensible to employ it.
Discussion
Previously, it was reported that reasonably
good predictions of human half-lives were
possible based exclusively on rat half-life
data (1). The predictive equation along
with upper and lower confidence limits
(80%, 90%, and 95%) were derived from a
regression analysis based upon human and
rat half-life values for 103 xenobiotics and
therefore differed from other allometrically
based predictions of toxicokinetic parame-
ters in humans for a given xenobiotic,
which depend upon the extrapolation
across multiple species ofthe estimates ofa
toxicokinetic parameter for asingle xenobi-
otic. The authors accounted for at least 12
different reasons for a wide range between
the upper and lower prediction limits sur-
rounding the regression line (i.e., scatter of
data) (1). None ofthose reasons addressed
the physical-chemical characteristics of
xenobiotics. We were interested to see
whether accounting for a xenobiotic's lipid
solubility might diminish the variance in
the data, particularly since fat comprises a
significandy larger fraction ofhuman body
weight compared to rats. This suggests that
the simple allometric expression relating rat
and human half-lives (see Equation 2)
might underpredict human half-lives of
highlylipophilic substances.
We incorporated a representation of
xenobiotic lipophilicity, the octanol:water
partition coefficient expressed as log P, into
our regression analysis and also expanded
the data set to include several xenobiotics
with extremely large log P values. The half-
life of a xenobiotic in rats or humans is a
function of the volume of distribution
(VD) and the total clearance rate (CL) as
given by the equation:
t1/2=0.693 VDICL (3)
V. is expected to increase with increasing
log P as more of the compound is distrib-
uted into adipose tissues and other lipid
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Figure 2. Actual human half-lives and human half-life prediction intervals plotted as a function of rat half-
livesforthe fitof Model 2tothe full data set(n = 127). Curves representthe predicted values, the 95% pre-
diction limits,the 90% prediction limits, and the 80% prediction limits.
environments of the body. CL is expected
to be inversely related to log P for com-
pounds principally eliminated by renal or
biliary excretion. The CL of substances,
dependent solely on biotransformation for
elimination, may be less strongly depen-
dent on log P. In any case, the tl/2 for a
given species can be expected to be corre-
lated with log P such that tl/2will generally
increase as log P increases. This prediction
is evidenced in Figure 4, which illustrates
that both rat and human half-life values
show a general trend to increase with
increasing log P for the large number of
xenobiotics considered in our analysis. On
the other hand, this figure demonstrates
that log P by itself is a relatively poor pre-
dictor oft1/2 for both rats and humans.
Consideration must then be given tohow
log P affects the relationship between human
half-lives and rat half-lives for an array of
xenobiotics. From Equation 3, the general
relationship between human half-lives andrat
half-lives can be written as a function of VD
and CLforeach species asfollows:
tl/2h = tll2r (VDh/VDr)(CrlCLh) (4)
For a given xenobiotic, the CL ratio can be
expected to be at least partly correlated with
relative bodysize (7,8, but notsystematically
affected by log P. Because ofahigher adipose
fraction in humans (23% for humans vs. 7%
for rats), however, the human VD can be
expected to increase morewith increasinglog
P than does the rat VD. The VD ratio, and
hence the ratio of human to rat half-life,
should then be generally larger for xenobi-
otics with high log P values than low log P
values. This is indicated in Figure 4, where
the disparity between rat and human half-
lives is seen to increase for substances with
large log P values. Explicitly accounting for
log P can, in fact, improve the accuracy of
human half-life predictions from rat half-life
data as noted by the improved predictions of
bothModels 3 and 4 versus Models 1 and 2,
respectively, when the same data set (i.e., n =
102) is used. Because rat half-life is at least
partiallyafunction oflog P (see Fig. 4), there
maybesufficient informationwithin an array
of rat half-lives to predict human half-lives
across the full range of log P values. This
explains why the use ofthe quadratic equa-
tion (Model 2) yielded RMSE values and
coefficients ofdetermination roughly compa-
rable to those ofModel 4, suggesting that the
quadratic equation can be effectively applied
to the prediction ofxenobiotic half-lives in
humans from rathalf-lifedata, evenfor xeno-
biotics that possess extremely long half-lives
and/or extremely large log P values such as
dioxins and polychlorinated biphenyls.
Moreover, Model 2 does not even require
knowledge oflog P values; it only requires a
measure ofxenobiotic half-life in the rat. It
Volume 105, Number 11, November 1997 . EnvironmentalHealth Perspectives 1206Articles * Estimating xenobiotic half-lives in humans from rat data
105
-C
S
a'
co
E
._
.5
S
U
a-
103
102
10
10-1
10-2
10-2 10- 10 102 103 1 10 10-3
Measured human half-life (hr)
-
U
.5
=
E
._
.5
S
U
.5
a-0
10-2 10-1 10 102 103 10 105
Measured human half-life (hr)
104
103 2
102
10,
10-1
10-2
10 10-3 E
1o-2 lo-, 10 102 103 104 105 10-3 10-2 10-1 10 102 102 10 105
~~~. .. ..
Measured human half-life (hr) Measured human half-life (hr)
Figure 3. Predicted human half-lives versus measured human half-lives. Predictions based on four models are shown as follows: (A) Model 1 ly= 1.4074(XO8187)];
(B) Model 2 [y= 1.2449 (X-87787)]; (C) Model 3 [y= 1.4118(XO8539)J; and (D) Model 4 [y= 1.3236 (X-8784)]. Equations for each regression were computed in all cases
only on the subset of data for which log P values were known (n = 102); however, additional data points (forwhich log P values were not known) are also exhibit-
ed in Model 1 and Model 2. The dashed line is the zero residual or identity line, which represents a perfectfit.
must be noted that Model 1 appears to break
down for xenobiotics with extremely large
log P (or half-life) values, and for such sub-
stances, the magnitude of human half-lives
can be greatly underpredicted by Model 1. It
might also be noted that methyl mercury,
with a low log P but a long half-life due to
unusual binding properties, is well accomo-
dated bythis same model.
As a practical matter, we found that
accounting for lipid solubility does improve
the accuracy ofpredictions ofhuman xeno-
biotic half-lives from rat half-life data and
decreases variance when log P values are
included in the prediction equation. (com-
pared to Model 4 versus Model 2 for equal
sample size). This is especially important
when predicting human half-lives from rat
half-lives for xenobiotics with extremely large
log P values (>6.5), where Model 1 (from
which the simple allometric expression in
Equation 2 isderived) can become inaccurate
(see Fig. 1 and Fig. 3A). Thus, Model 4
should be used whenever log P and rat half-
life data are both readily available. In many
cases, however, log P values may not be
known apriori for the molecule of interest.
Environmental Health Perspectives * Volume 105, Number 11, November 1997
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And for environmental chemicals such as
dioxins, polyhalogenated biphenyls, and
polyhalogenated dibenzofurans, it is reason-
able to assume that log P values may be
extremely large. When log P values are not
known, we recommend the application of
the quadratic equation shown in Model 2 for
predicting human half-lives from rat half-
lives because this model appears to provide
accurate predictions over the full range of
106
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Figure 4. Human half-lives (log t112 = 0.452 + 0.288 log P; r=0.647) and rat half-lives (log tl/2 = 0.161 + 0.209 log P; r=0.568) as a function oflog P.
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xenobiotic half-lives likely to be encountered
and does so without the need for an explicit
value of a xenobiotic's aqueous/lipid parti-
tioning.
REFERENCES
1. Bachmann K, Pardoe D, White D. Scaling basic
toxicokinetic parameters from rat to man.
Environ Health Perspect 104:400-407 (1996).
2. Reitz R, Gargas M, Andersen M, Provan W,
Green T. Predicting cancer risk from vinyl chlo-
ride exposure with a physiologically-based phar-
macokinetic model. Toxicol Appl Pharmacol
137:253-267 (1996).
3. Hansch C, Leo A, Hoekman D. Exploring QSAR
Hydrophobic, Electronic, and Steric Constants.
Washington, DC:American Chemical Society,
1995.
4. Craig P. Drug compendium. In: Comprehensive
Medicinal Chemistry: The Rational Design,
Mechanistic Study and Therapeutic Application
of Chemical Compounds, Vol 6 (Hansch C,
Sammes P, Taylor J, eds). New York:Pergamon
Press,1990;237-965.
5. Environmental Science Center, Syracuse Research
Corporation. http://esc.syrres.com (1996).
6. Leo A, Hansch C, Hoekman D. MacLogP
Database, version 2.0. Claremont, CA:Biobyte
Corp., 1996.
7. Boxenbaum H. Interspecies scaling, allometry,
physiological time, and the ground plan ofphar-
macokinetics. J Pharmacokin Biopharm
10:201-227 (1982).
8. Travis CC, White RK, Ward RC. Interspecies
extrapolation of pharmacokinetics. J Theor Biol
142:285-304 (1990).
9. Fisher HL, Shah PV, Hall LL. In vivo and vitro
dermal penetration of 2,4,5,2',4',5' hexa-
chlorobinphenyl in young adult rats. Environ Res
50:120-139 (1989).
10. Van der Berg M,JonghJ, Poiger H, Olson J. The
toxicokinetics and metabolism ofpolychlorinated
dibenzo-p-dioxins (PCDDs) and dibenzofurans
(PCDFs) and their relevance for toxicity. Crit
RevToxicol 24:1-74 (1994).
11. Corley RA, Bormett GA, Ghanayem BI.
Physiologically based pharmacokinetics of 2-
butoxyethanol and its major metabolite, 2-
butoxyacetic acid, in rats and humans. Toxicol
Appl Pharmacol 129:61-79 (1994).
12. Laine K, Kivisto, KT, Neivonen PJ. Failure of
oral activated charcoal to accelerate the elimina-
tion of amiodarone and chloroquine. Hum Exp
Toxicol 11:491-494 (1992).
13. Gill J, Heel RC, Fitton A. Amiodarone: an
overview of its pharmacological properties and
review of its therapeutic use in cardiac arrhyth-
mias. Drugs 43:69-110 (1992).
14. Teramura T, Watanabe T, Higuchi S, Hashimoto
K Pharmacokinetics ofbarnidipine hydrochloride,
a new dihydropyridine calcium channel blocker, in
the rat, dog, and human. Xenobiotica 25:
1237-1246 (1995).
15. Chen L, Yang C. Effects ofcytochrome P4502E1
modulators on the pharmacokinetics ofchlorzox-
azone and 6-hydroxychlorzoxazone in rats. Life
Sci 58:1575-1585 (1996).
16. Bachmann K, Sarver J. Chlorzoxazone as a single
sample probe of hepatic CYP2E1 activity in
humans. Pharmacology 52:169-177 (1996).
17. Kharidia J, Eddington ND. Effects ofdesethyl-
amiodarone on the electrocardiogram in
1208 Volume 105, Number 11, November 1997 * EnvironmentalHealth PerspectivesArticles * Estimating xenobiotic half-lives in humans from rat data
conscious freely movinganimals. Pharmaco-kinetic
and pharmacodynamic modeling using computer-
assisted radio telemetry. Biopharm Drug Dispos
17:93-106 (1996).
18. Ujhelyi M, Kiamens K, Vadei K, O'Rangers E,
Izard M, Neefe L, Zimmerman J, Chow M.
Disposition of intravenous amiodarone in subjects
with normal and impaired renal function. J Clin
Pharmacol 36:122-130 (1996).
19. Grene-Lerouge N, Bazin-Redureau M, Debray M,
Scherrmann J. Interspecies scaling ofclearance and
volume of distribution for digoxin-specific fab.
ToxicolAppl Pharmacol 138:84-89 (1996).
20. Thanh-Barthet CV, Urtizberea M, Sabouraud
AE, Cano NJ, Schermann JM. Development ofa
sensitive radioimmunoassay for fab fragments:
application to fab pharmacokinetics in humans.
Pharm Res 10:692-696 (1993).
21. Lave T, Dupin S, Schmitt M, Kapps M, Meyers J,
Morgenroth B, Chou RC, Jaeck D, Coassolo P.
Interspecies scaling oftolcapone, a new inhibitor of
catechol-o-methyltransferase (COMT). Use of in
vitro data from hepatocytes to predict metabolic
clearance in animals and humans. Xenobiotica
8:839-851 (1996).
22. Frantz SW, Beskitt JL, Tallant MJ, Zourelias LA,
Ballantyne B. Pharmacokinetics ofethylene glycol
III. Plasma disposition and metabolic fate after
single increasing intravenous, peroral, or percuta-
neous doses in the male Sprague-Dawley rat.
Xenobiotica 26:515-539 (1996).
23. Jacobson D, Hewlett TP, Webb R, Brown ST,
Ordinario AT, McMartin KE. Ethylene glycol
intoxication: evaluation of kinetics and crystal-
luria.AmJ Med 84:145-152 (1988).
24. Brown C, Wong B, Fennell T. In vivo and in vitro
kinetics of ethylene oxide metabolism in rats and
mice. ToxicolAppl Pharmacol 136:8-19 (1996).
25. Filser JG, Denk B, Tornqvist W, Ehrenberg L.
Pharmacokinetics ofethylene in man; body burden
with ethylene oxide and hydroxyethylation of
hemoglobin due to endogenous and environmental
ethylene. ArchToxicol 66:157-163 (1992).
26. Anonymous. Clinical Investigator's Information
Brochure for IND 966. NewJersey, 1995.
27. Sarver JG. Development ofa tracer technique that
utilizes a physiological pharmacokinetic model to
quantitatively assess the change in mass transfer
rates associated with vascular growth and the appli-
cation ofthis technique to the evaluation ofa novel
bioartifical organoid [Ph.D. dissertation]. The
UniversityofToledo,Toledo, Ohio, 1994.
28. Prescott L, McAuslane J, Freestone S. The concen-
tration-dependent disposition and kinetics of
inulin. EurJ Clin Pharmacol 40:619-624 (1991).
29. Freestone S, McAuslane JA, Prescott LF. Effects
of tenoxicam on renal function and the disposi-
tion of inulin and p-aminohippurate in healthy
volunteers and patients with chronic renal failure.
BrJ Clin Pharmacol 32:495-500 (1991).
30. Borghoff SJ, Murphy JE, Medinsky MA.
Development of a physiologically based pharma-
cokinetic model for methyl tertiary-butyl ether
and tertiary-butanol in male Fischer-344 rats.
Fundam Appl Toxicol 30:264-275 (1996).
31. Johnson G, Nihlen A, LofA. Toxicokinetics and
acute effects ofMTBE and ETBE in male volun-
teers. Toxicol Lett 82/83:713-718 (1995).
32. MordentiJ, Osaka G, Garcia K, Thomsen K, Licko
V, MengG. Pharmacokinetics and interspecies scal-
ing of recombinant human factor VIII. Toxicol
Appl Pharmacol 136:75-78 (1996).
33. Filser JG, Schwegler U, Csanady GA, Greim H,
Kreuzer PE, Kessler W. Species-specific pharma-
cokinetics of styrene in rat and mouse. Arch
Toxicol 67:517-530 (1993).
34. Brugnone F, Perbellini L, Wang GZ, Maranelli
G, Raineri E, DeRosa E, Saletti C, Soave C,
Romeo L. Blood styrene concentrations in a "nor-
mal" population and in exposed workers 16 hours
after the end of the work shift. Int Arch Occup
Environ Health 65:125-130 (1993).
35. Robinson SP, Langan-Fahey SM, Johnson DA,
Jordan VC. Metabolites, pharmacodynamics, and
pharmacokinetics of tamoxifen in rats and mice
compared to the breast cancer patient. Drug
Metab Dispos 19:36-43 (1991).
36. Lonning PE, Lien EA, Lundgren S, Kvinnsland S.
Clinical pharmacokinetics ofendocrine agents used
in advanced breast cancer. Clin Pharmacokinet
22:327-358 (1992).
37. Ebling WF, Wada DR, Stanski DR From piece-
wise to full physiologic pharmacokinetic model-
ing:applied to thiopental disposition in the rat. J
Pharmacokinet Biopharm 22:259-292 (1994).
38. Homer TD, Stanski DR. The effect of increasing
age on thiopental disposition and anesthetic
requirement. Anesthesiology 62:714-724 (1985).
39. Lave T, Dupin S, Schmitt M, Kapps M, Meyers J,
Morgenroth B, Chou RC, Jaeck D, Coassolo P.
Interspecies scaling oftolcapone, a new inhibitor of
catechol-o-methyltransferase (COMT). Use of in
vitro data from hepatocytes to predict metabolic
clearance in animals and humans. Xenobiotica
8:839-851 (1996).
40. Teng R, Girard D, GootzTD, Flouds G, Liston T.
Pharmacokinetics of trovafloxacin (CP-99,219), a
new quinolone, in rats, dogs and monkeys.
Antimicrob Agents Chemother 40:561-566
(1996).
41. Teng R, Harris SC, Nix DE, Schentag JJ, Flouds
G, Liston TE. Pharmacokinetics and safety of
trovafloxacin (CP-99,219), a new quinolone
antibiotic, following administration ofsingle oral
doses to healthy male volunteers. J Antimicrob
Chemother 36:385-394 (1995).
42. Metha S, Lu D. Interspecies pharmacokinetic
scaling of BSH on mice, rats, rabbits, and
humans. Biopharm Drug Dispos 16:735-744
(1995).
43. Weber LWD, Greim H. The toxicity of bromi-
nated and mixed-halogenated dibenzo-p-dioxins
and dibenzofurans: an overview. J Toxicol
Environ Health 50:195-215 (1997).
44. Matthews HB, Andersen MW. Effect of chlori-
nation on the distribution and excretion ofpoly-
chlorinated biphenyls. Drug Metab Dispos
3:371-380 (1975).
45. ShiraiJH, KisselJC. Uncertainty in estimated half-
lives of PCBs in humans: impact on exposure
assessment. Sci Total Environ 187:199-210
(1996).
n a *sIIl------------ILSI International LifeSciences Institute
Third Asian Conference on FoodSafety and Nutrition
1Pg 5 T ITUT September 14 17 1998
Beiing,China
- Sponsored by:
InternationalUfeSciencesInstitute(ILSI)
ILSI FocalPointinChina
ChineseAcademyofPreventiveMAedicine
Environmental Health Perspectives * Volume 105, Number 11, November 1997 1209